Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 3/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745266 | 0.99 | GRIN2D (0.44) | GRIN2DGRIN2AGRIN2CPTPN1TTR | |
| SCHEMBL860353 | 0.99 | GRIN2D (0.44) | GRIN2DGRIN2AGRIN2CPTPN1TTR | |
| SCHEMBL745566 | 0.99 | GRIN2D (0.44) | GRIN2DGRIN2AGRIN2CPTPN1TTR | |
| SCHEMBL742864 | 0.85 | ALDH1A1 (0.41) | GRIN2DGRIN2AGRIN2CPTPN1TTR | |
| SCHEMBL742346 | 0.84 | ALDH1A1 (0.42) | GRIN2DGRIN2AGRIN2CPTPN1TTR | |
| SCHEMBL3368674 | 0.81 | PTPN1 (0.58) | GRIN2DGRIN2AGRIN2CPTPN1MAPT | |
| SCHEMBL7915823 | 0.80 | PLA2G2D (0.50) | GRIN2DGRIN2AGRIN2CPTPN1TTR | |
| SCHEMBL11243982 | 0.79 | ESR2 (0.44) | MCL1MAPTKDM4EGAAKMT2A | |
| SCHEMBL14120700 | 0.79 | ESR2 (0.44) | MCL1MAPTKDM4EGAAKMT2A | |
| SCHEMBL29774152 | 0.79 | GRIN2D (0.60) | GRIN2DGRIN2AGRIN2CPTPN1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BPGBIO INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | BPGBIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-2983654-B1 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGBIO INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | BPGBIO, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | BPGBIO, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | BERG LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BERG, KARA ANN | 2022-06-30 | — | — | US | disclosed |
| US-20220096399-A1 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 | BERG LLC (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220096400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | THLIVERIS, ANDREW T. | 2022-03-31 | — | — | US | disclosed |
| US-20110064747-A1 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG PHARMA LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2010132479-A2 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132502-A2 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132507-A2 | METHODS FOR TREATMENT OF DISEASE USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132440-A2 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-0932701-A1 | STRUCTURAL AND FUNCTIONAL CONSERVATION OF THE C. ELEGANS CLOCK GENE clk-1 | McGILL UNIVERSITY (CA) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998017823-A1 | STRUCTURAL AND FUNCTIONAL CONSERVATION OF THE C. ELEGANS CLOCK GENE $i(clk-1) | MCGILL UNIVERSITY (CA) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | SLC25A20, NDUFB10, NDUFA10 | GRIN2D 3429/4885GRIN2A 2624/4885GRIN2C 2941/4885 |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | VEGFA, NDUFA10, NDUFB10 | GRIN2D 1247/4885GRIN2A 1923/4885GRIN2C 3062/4885 |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | GRIN2D 1512/4885GRIN2A 716/4885GRIN2C 1249/4885 |
| US-20220096400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | NDUFA10, NDUFB10, NDUFA5 | GRIN2D 4171/4885GRIN2A 4173/4885GRIN2C 4504/4885 |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFA10, NDUFB10, NDUFA5 | GRIN2D 547/4885GRIN2A 1160/4885GRIN2C 1758/4885 |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | PC, GLS2, PCK2 | GRIN2D 4103/4885GRIN2A 3299/4885GRIN2C 3445/4885 |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | SLC25A20, NDUFB10, NDUFA10 | GRIN2D 3429/4885GRIN2A 2624/4885GRIN2C 2941/4885 |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | NDUFB10, NDUFA10, COQ8A | GRIN2D 1893/4885GRIN2A 645/4885GRIN2C 1146/4885 |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | NDUFB10, NDUFA10, NDUFB5 | GRIN2D 1512/4885GRIN2A 716/4885GRIN2C 1249/4885 |
| US-20220096399-A1 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | GRIN2D 4322/4885GRIN2A 3594/4885GRIN2C 3888/4885 |
| US-20110064747-A1 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | NDUFB10, SDHB, SDHA | GRIN2D 4745/4885GRIN2A 4652/4885GRIN2C 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.